Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
Main Article Content
Keywords
Azacytidine; MDS; failure; real life
Abstract
N/A
Downloads
Download data is not yet available.
Abstract 785
PDF Downloads 595
HTML Downloads 140
References
1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology. 2009 Mar;10(3):223-32.
2. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacytidine treatment failure. J Clin Oncol. 2011 Aug 20;29(24):3322-7.
3. Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, et al. Poor outcome of patients with myelodysplastic syndrome after azacytidine treatment failure. Clinical lymphoma, myeloma & leukemia. 2013 Dec;13(6):711-5.
4. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 Jun;101(6):e224-7.
5. Prebet T, Fenaux P, Vey N, Groupe Francophone des M. Predicting outcome of patients with myelodysplastic syndromes after failure of azacytidine: validation of the North American MDS consortium scoring system. Haematologica. 2016 Oct;101(10):e427-e8.
6. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25.
7. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacytidine. Blood. 2011 Jan 13;117(2):403-11.
8. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15;121(6):876-82.
9. Prebet T, Thepot S, Gore SD, Dreyfus F, Fenaux P, Vey N. Outcome of patients with low-risk myelodysplasia after azacytidine treatment failure. Haematologica. 2013 Feb;98(2):e18-9.
10. Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacytidine failure. Leuk Res. 2015 May;39(5):501-4.
11. Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clinical lymphoma, myeloma & leukemia. 2017 Apr;17(4):211-4.
12. Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, et al. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematological oncology. 2018 Aug 20.
13. Kim DJ, Lee HS, Moon JH, Sohn SK, Kim HJ, Cheong JW, et al. Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget. 2017 Oct 3;8(45):79414-24.
14. Komrokji RS. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents. Clinical lymphoma, myeloma & leukemia. 2015 Jun;15 Suppl:S56-9.
15. Patel SS, Sekeres MA, Nazha A. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. Leukemia & lymphoma. 2017 Nov;58(11):2532-9.
2. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacytidine treatment failure. J Clin Oncol. 2011 Aug 20;29(24):3322-7.
3. Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, et al. Poor outcome of patients with myelodysplastic syndrome after azacytidine treatment failure. Clinical lymphoma, myeloma & leukemia. 2013 Dec;13(6):711-5.
4. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 Jun;101(6):e224-7.
5. Prebet T, Fenaux P, Vey N, Groupe Francophone des M. Predicting outcome of patients with myelodysplastic syndromes after failure of azacytidine: validation of the North American MDS consortium scoring system. Haematologica. 2016 Oct;101(10):e427-e8.
6. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25.
7. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacytidine. Blood. 2011 Jan 13;117(2):403-11.
8. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15;121(6):876-82.
9. Prebet T, Thepot S, Gore SD, Dreyfus F, Fenaux P, Vey N. Outcome of patients with low-risk myelodysplasia after azacytidine treatment failure. Haematologica. 2013 Feb;98(2):e18-9.
10. Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacytidine failure. Leuk Res. 2015 May;39(5):501-4.
11. Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clinical lymphoma, myeloma & leukemia. 2017 Apr;17(4):211-4.
12. Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, et al. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematological oncology. 2018 Aug 20.
13. Kim DJ, Lee HS, Moon JH, Sohn SK, Kim HJ, Cheong JW, et al. Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget. 2017 Oct 3;8(45):79414-24.
14. Komrokji RS. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents. Clinical lymphoma, myeloma & leukemia. 2015 Jun;15 Suppl:S56-9.
15. Patel SS, Sekeres MA, Nazha A. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. Leukemia & lymphoma. 2017 Nov;58(11):2532-9.